Core Viewpoint - Shanghai Baiying Biotechnology Co., Ltd. (Baiying Bio) is preparing for its IPO on the Beijing Stock Exchange, with a focus on antibody and protein expression services, and is responding to inquiries regarding its revenue recognition policies [2][6]. Group 1: Company Overview - Baiying Bio specializes in contract research organization (CRO) services, particularly in antibody and protein expression, as well as antibody discovery and optimization [6]. - The company has developed a high-throughput, high-expression, and rapid delivery platform for antibody and protein expression, aiming to provide one-stop antibody discovery services [6]. - Baiying Bio is actively expanding its overseas market, with the proportion of overseas business increasing year by year [6]. Group 2: Financial Performance - Baiying Bio's revenue for the years 2022 to 2024 is projected to be 260 million yuan, 338 million yuan, and 402 million yuan, respectively [6]. - The net profit for the same period is expected to be 57.65 million yuan, 84.02 million yuan, and 124 million yuan, respectively [6]. - The gross profit margin is forecasted to be 65.88%, 66.15%, and 70.04% for the years 2022, 2023, and 2024, respectively [6]. Group 3: Revenue Recognition Policies - Baiying Bio has different revenue recognition points for domestic and international clients, with domestic clients confirming revenue upon receipt of acceptance emails, while international clients do so upon sending completion emails [2][4]. - The company operates two revenue recognition models: order-based settlement and monthly settlement, which need to be analyzed for their commercial rationality and compliance with industry practices [4][5]. - The inquiry from the Beijing Stock Exchange requires Baiying Bio to detail the revenue recognition policies, execution cycles, and the rationale behind the monthly settlement model, including its stability and potential risks [5].

Core Viewpoint - Shenyang Guantai Vacuum Technology Co., Ltd. (referred to as "Guantai Vacuum") has had its IPO meeting postponed, raising concerns regarding revenue recognition practices and project acceptance timelines [1] Group 1: Company Overview - Guantai Vacuum specializes in the research, manufacturing, and sales of vacuum equipment, demonstrating integrated capabilities from independent design to manufacturing delivery [1] - The company aims to raise approximately 168 million yuan through its IPO [1] Group 2: IPO Review and Concerns - The listing committee has requested Guantai Vacuum to verify the status of projects that have not been accepted for over one year after delivery, detailing shipment times, receipt times, debugging times, initial acceptance times, and on-site service times [1] - The committee has raised questions about the accuracy and sufficiency of revenue recognition, particularly for projects with delivery to acceptance times exceeding 15 months, requiring clarification on major contract terms and performance [1] - Guantai Vacuum is also asked to provide details on its contract with Jiangsu Pacific Quartz Co., Ltd., including the main content of the contract, execution status, and any subsequent breach handling processes [1]